Prelude Therapeutics Incorporated · NASDAQ:PRLD
Prelude Therapeutics — ASH Annual Meeting 2022
11 slides from Prelude Therapeutics's conference presentation, 2022
Slide 1: PRT2527, a Novel, Highly Selective CDK9 Inhibitor, Has Potent Anti-Leukemic Activity
PRT2527, a Novel, Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Models of Lymphoid Malignancies Neha Bhagwat1, Bruce Ruggeri1, Yang Zhang1, Yaron Mosesson2, Clare Killick-Cole2, Veena Jagannathan2, Peggy Scherle1 Affiliations: 1Prelude
Slide 2: CDK9: Targeting Cancer Through Transcriptional Regulation
CDK9: Targeting Cancer Through Transcriptional Regulation CDK9 phosphorylates RNA Pol II and regulates transcription Regulates expression of several immediate early genes driving oncogenesis and resistance (i.e. MYC, MCL1) Non-selective CDK9 inhibitors have demonstrated clinical activity in multiple
Slide 3: PRT2527: Potent and Highly Selective CDK9 Inhibitor Candidate
PRT2527: Potent and Highly Selective CDK9 Inhibitor Candidate Highly Selective, ATP Competitive Compound PRT2527 CDK9 Inhibitor Candidate Biochemical* IC50 (nM) CDK9 0.95 Proliferation* IC50 (nM) 18 PRT2527 Plasma* IC50 (nM) 196 177 Assays tested CDK1 73x 3 Interactions Mapped S-Score(35) = 0.02 CDK
Slide 4: PRT2527 Treatment Induces Depletion of MCL1 and MYC in Preclinical Models
PRT2527 Treatment Induces Depletion of MCL1 and MYC in Preclinical Models PRT2527 (nM) PRT2527 i.v. 15 mg/kg BID Transient treatment of MV4-11 cells with PRT2527 for 4 hours leads IV administration of PRT2527 at 15 mg/kg BID (q2h) achieves to inhibition of phospho-RNAPol2, and depletion of MCL1 and
Slide 5: PRT2527 demonstrates broad anti-proliferative activity in hematologic malignancy cell lines
PRT2527 demonstrates broad anti-proliferative activity in hematologic malignancy cell lines Median IC50 – 45 nM ASH Annual Meeting 2022 Abstract No. 210
Slide 6: PRT2527 is Highly Efficacious In Vivo in CDX and PDX Models of Hematologic Malignancies
PRT2527 is Highly Efficacious In Vivo in CDX and PDX Models of Hematologic Malignancies Intermittent IV administration of PRT2527 is highly efficacious in CDX/PDX double-hit/triple-hit DLBCL models with MYC translocation PRT2527 demonstrates anti-tumor activity in AML models • Achieved complete regr
Slide 7: PRT2527 is Potent in CLL Primary Cultures Ex vivo
PRT2527 is Potent in CLL Primary Cultures Ex vivo Median IC50 - 30 nM in a proliferation assay *Prior tx included FCR and an experimental autologous T-cell infusion #Prior tx included Chlorambucil and Rituximab/Bendamustine ASH Annual Meeting 2022 Abstract No. 210
Slide 8: PRT2527 Demonstrates Significant Anti-Tumor Activity in Models of B-ALL and T-ALL
PRT2527 Demonstrates Significant Anti-Tumor Activity in Models of B-ALL and T-ALL PRT2527 activity in ALL was observed in 5/6 T-ALL and Significant survival benefit observed with once weekly 10/10 B-ALL primary patient samples in an ex vivo assay PRT2527 treatment in a highly aggressive KMT2A- rearr
Slide 9: Phase 1 dose-escalation study of PRT2527 in advanced solid tumors
Phase 1 dose-escalation study of PRT2527 in advanced solid tumors (NCT05159518) Phase 1 dose escalation study of PRT2527 is Dose-dependent inhibition of CDK9 ongoing and enrolling following tumor types transcription targets observed in PBMCs • selected sarcomas displaying a gene fusion • Castrate re
Slide 10: Summary
Summary PRT2527 is potent and selective CDK9 inhibitor that demonstrates robust activity in preclinical models of hematologic malignancies with once weekly dosing • Activity observed in models that are insensitive to current SoC as well as in combination with targeted agents PRT2527 was well-tolerat
Slide 11: Thank you
PRT2527, a Novel, Highly Selective Cyclin-Dependent Thank you Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Models of Lymphoid Malignancies Neha Bhagwat1, Bruce Ruggeri1, Yang Zhang1, Yaron Mosesson2, Clare Killick-Cole2, Veena Jagannathan2, Peggy Scherle1 Affiliations: